Literature DB >> 11739083

IGFBP-3 binding to endothelial cells inhibits plasmin and thrombin proteolysis.

B A Booth1, M Boes, B L Dake, K L Knudtson, R S Bar.   

Abstract

Insulin-like growth factor-binding protein (IGFBP)-3 contains a highly basic COOH-terminal heparin-binding region, the P3 region, which is thought to be important in the binding of IGFBP-3 to endothelial cells. IGFBP-3 and IGFBP-4, and their chimeras IGFBP-3(4) and IGFBP-4(3), were treated with plasmin and with thrombin, proteases known to cleave IGFBP-3. IGFBP-3 was highly susceptible to plasmin, whereas IGFBP-4 was less so. Substitution of the P3 region for the P4 region in IGFBP-4 (IGFBP-4(3)) increased the ability of the protease to digest IGFBP-4(3); substitution of the P4 region for the P3 region in IGFBP-3 (IGFBP-3(4)) decreased the digestion of IGFBP-3(4). When 125I-labeled IGFBP-3 or 125I-IGFBP-4(3) was first bound to vascular endothelial cells, subsequent proteolysis by either plasmin or thrombin was substantially inhibited. Proteolysis of 125I-IGFBP-3(4) was not inhibited in the presence of endothelial cells. The P3 peptide was cleaved by plasmin but not by thrombin. We conclude that the P3 region is central to proteolysis of IGFBP-3 by plasmin and thrombin, processes which were inhibited by association of IGFBP-3 with endothelial cells.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11739083     DOI: 10.1152/ajpendo.2002.282.1.E52

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  2 in total

1.  Open surgery induces a dramatic decrease in circulating intact IGFBP-3 in patients with colorectal cancer not seen with laparoscopic surgery.

Authors:  I Kirman; V Cekic; N Poltoratskaia; P Sylla; S Jain; K A Forde; R L Whelan
Journal:  Surg Endosc       Date:  2004-11-11       Impact factor: 4.584

2.  Identification of ageing-associated naturally occurring peptides in human urine.

Authors:  Esther Nkuipou-Kenfack; Akshay Bhat; Julie Klein; Vera Jankowski; William Mullen; Antonia Vlahou; Mohammed Dakna; Thomas Koeck; Joost P Schanstra; Petra Zürbig; Karl L Rudolph; Björn Schumacher; Andreas Pich; Harald Mischak
Journal:  Oncotarget       Date:  2015-10-27
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.